Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients-Reference-Cited by-同舟云学术

Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients

Published:2019-04 Issue:4 Volume:25 Page:656-663
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Hamadeh Issam S.,Zhang Qing,Steuerwald Nury,Hamilton Alicia,Druhan Lawrence J.^ORCID,McSwain Meredith,Diez Yordanis,Rusin Stephanie,Han Yimei,Symanowski James,Gerber Jonathan,Grunwald Michael R.,Ghosh Nilanjan,Plesca Dragos,Arnall Justin,Trivedi Jigar,Avalos Belinda,Copelan Edward,Patel Jai N.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference38 articles.

1. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors;Nash;Blood,1996

2. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation;Fay;Blood,1996

3. Clinical pharmacokinetics of tacrolimus;Venkataramanan;Clin Pharmacokinet,1995

4. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring;Trifilio;Bone Marrow Transplant,2010

5. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients;Bottiger;Br J Clin Pharmacol,1999

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation;Pharmaceuticals;2024-04-25

2. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant;Genes;2024-04-16

3. CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation;Frontiers in Pharmacology;2024-01-08

4. Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients;Pharmacogenomics;2024-01

5. Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens;Best Practice & Research Clinical Haematology;2023-06